StockIQ.techIllumina, Inc. (ILMN) Stock Analysis
Free AI-powered analysis and research for Illumina, Inc. stock
Sector: Healthcare
ILMN snapshot
Data as of 3 Nov 2026 close. Updated daily.
Illumina, Inc. scores 68/100 on StockIQ's model, which reads as positive signals overall. The price is above its 200-day average and at 64% of its 52-week range, up 98.4% over the past year. Latest reported figures show a profit margin of 19.7%, return on equity of 32.4% and revenue growth of +4.2%.
What is driving the score
- RSI Neutral: +5
- Mixed Trend: +0
- MACD Bearish: -8
- High P/E (44.0): -10
- Good Profit Margin (19.7%): +5
- Strong Liquidity (2.62 Current Ratio): +8
- Excellent ROE (32.4%): +8
- High P/B (13.26): -5
- Strong Long-term Uptrend: +8
- Strong Rise (+98.4% over 1 year): +10
- Low Volume (0.4x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full ILMN report
Illumina, Inc. (ILMN) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze ILMN Now →📰 Latest Update
Forensic Technologies and Services - Global Strategic Business Report: Secure Share of a $44.7B Market by 2030 as Thermo Fisher, Illumina, Agilent and BAE Systems Accelerate AI-Led Forensics
Mon, November 2, 2026 at 3:49 PM UTC 3 min read
The global forensic technologies and services market, valued at US$24 billion in 2024, is projected to reach US$44.7 billion by 2030, growing at a compound annual growth rate of 10.9%. Key drivers include rising demand for advanced investigative capabilities, particularly in response to cybercrime, and technological innovations such as AI and next-generation DNA sequencing. Major companies in this space include Thermo Fisher, Illumina, and Agilent, with significant growth opportunities identified in various applications and regions.